Shumilov, Evgenii; Shakhanova, Inna; Flach, Johanna; Schmidt, Nicole; Buerki, Susanne; Legros, Myriam; Kronig, Marie-Noëlle; Ofran, Yishai; Gerull, Sabine; Medinger, Michael; Mansouri Taleghani, Behrouz; Passweg, Jakob; Halter, Jörg; Bacher, Ulrike; Pabst, Thomas (2022). Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation. Bone marrow transplantation, 57(2), pp. 224-231. Springer Nature 10.1038/s41409-021-01521-5
|
Text
Feasibility_and_efficacy_of_salvage.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (691kB) | Preview |
Autologous hematopoietic cell transplantation (HCT) is suitable for consolidation of favorable-/intermediate-risk AML patients in CR1. However, ~50% of AML patients relapse after autologous HCT, and efficacy of subsequent salvage strategies including allogeneic HCT remains unclear. We studied 123 consecutive patients with newly diagnosed AML undergoing high-dose chemotherapy (HDCT)/autologous HCT in CR1. In relapsing patients afterwards, we analyzed salvage treatments and outcomes focusing particularly on salvage allogeneic HCT. Of 123 patients, 64 (52%) relapsed after autologous HCT. Subsequently, 13 (21%) received palliative therapy, whereas 51 (79%) proceeded to salvage therapy with a curative intent. Of the 47 patients with a curative intent and who did not proceed directly to allogeneic HCT, 23 (49%) achieved CR2 or had ongoing hematologic CR1 despite molecular relapse. Finally, 30 patients (47%) received allogeneic HCT with estimated 3-year leukemia-free and overall survival rates of 33% and 43%. Hematologic remission at allogeneic HCT and lack of acute GvHD had a positive impact on OS and LFS (p < 0.05). Our study suggests that almost 80% of AML patients can undergo salvage therapy following relapse after front-line HDCT/autologous HCT. Allogeneic HCT can provide cure in one third of patients relapsing after front-line HDCT/autologous HCT.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory 04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Bürki, Susanne, Legros, Myriam, Kronig, Marie-Noëlle, Mansouri Taleghani, Behrouz, Bacher, Vera Ulrike, Pabst, Thomas Niklaus |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1476-5365 |
Publisher: |
Springer Nature |
Language: |
English |
Submitter: |
Pierrette Durand Lüthi |
Date Deposited: |
26 Nov 2021 15:09 |
Last Modified: |
05 Dec 2022 15:55 |
Publisher DOI: |
10.1038/s41409-021-01521-5 |
PubMed ID: |
34775480 |
BORIS DOI: |
10.48350/161607 |
URI: |
https://boris.unibe.ch/id/eprint/161607 |
Actions (login required)
 |
Edit item |